Keywords
prevalencia
tratamiento
niños
actualización
Abstract
Allergic rhinitis (AR) is the most frequent allergic disease. Prevalence in children and teenagers in Argentina ranges between 22.3% and 34.9%. Given this situation, members of the scientific committees of Pediatrics and Rhinitis of the Argentinian Association of Allergy and Clinical Immunology (AAAeIC) have reviewed scientific evidence in order to update the therapeutic regulations of this pathology in the pediatric population. The classification and categorization of AR are currently in full review all around the world. It is necessary to make a differential diagnosis with other non-allergic types of rhinitis in children, and to confirm AR based on the clinical history, physical examination, determination of bio-markers, and/or skin tests. Non-pharmacological treatment includes education and guidelines of environmental control for allergens such as dust mites, anemophilous fungi, animal epithelium, and pollens. Step pharmacological therapy is proposed according to the control of the disease. Second-generation, non-sedating anti-histamines are the first line of therapy. The association with oral decongestants is not recommended in children under 4 years of age. Inhaled corticosteroids are the first choice for both moderate and severe forms. This document warns pediatricians about the importance of an early diagnosis, the rational use of step pharmacological therapy, and specific immunotherapy in children.References
Baena-Cagnani CE, Solé D, González-Díaz SN, Zernotti ME, Sisul JC, Sánchez BM, et al. Actualización de rinitis alérgica y su impacto en el asma (ARIA 2008). La perspectiva latinoamericana. Rev Alerg Mex. 2009;56(2):56-63.
Baena-Cagnani CE, Canonica GW, Zaky-Helal M, Maximiliano-Gómez R, Compalati E, et al. The international survey on the management of allergic rhinitis by physicians and patients (ISMAR). World Allergy Organ J. 2015;8(1):10. DOI: 10.1186/s40413-015-0057-0
Wheatley LM, Togias A. Clinical practice. Allergic Rhinitis. N Engl J Med. 2015;372(5):456-563. DOI: 10.1056/NEJMcp1412282
Neffen H, Mello JF Jr, Wingertzahn M, Solé D, Naspitz CK, Dodero AE, et al. Nasal allergies in the Latin American population: results from the Allergies in Latin America Survey. Allergy Asthma Proc. 2010;31(Suppl 1):9-27. DOI: 10.2500/aap.2010.31.3347
Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multi-country cross-sectional surveys. Lancet 2006;368:733-43.
Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2018;372:1049-57.
Vázquez D, Medina I, Logusso G, Arias S, Gattolin G, Parisi C. Encuesta transversal sobre la prevalencia de rinitis alérgica en Argentina: el estudio PARA. Rev Alerg Mex. 2019;66(1):55-64. DOI: 10.29262/ram.v66i1.543
Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958. DOI: 10.1016/j.jaci.2017.03.050
Campo P, Salas M, Blanca-López N, Rondón C. Local allergic rhinitis. Immunol Allergy Clin North Am. 2016;36(2):321-332. DOI: 10.1016/j.iac.2015.12.008
Altıntoprak N, Kar M, Bayar Muluk N, Oktemer T, Ipci K, Birdane L, et al. Update on local allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2016;87:105-109. DOI: 10.1016/j.ijporl.2016.06.008
Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC, et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016;6:47. DOI: 10.1186/s13601-016-0137-4
Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1437-1458. DOI: 10.1016/j.jaci.2016.03.010
Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):51. DOI: 10.1186/s13223-018-0280-7
Cheng L, Chen J, Fu Q, He S, Li H, Tan G, et al. Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2018;10(4):300-353. DOI: 10.4168/aair.2018.10.4.300
Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017;47(7):856-889. DOI: 10.1111/cea.12953
Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-454. DOI: 10.1038/nature07204
Anto JM, Bousquet J, Akdis M, Auffray C, Keil T, Momas I, et al. Mechanisms of the Development of Allergy (MeDALL): introducing novel concepts in allergy phenotypes. J Allergy Clin Immunol. 2017;139(2):388-399. DOI: 10.1016/j.jaci.2016.12.940
Comité Nacional de Alergia, Comité Nacional de Neumonología, Comité de Otorrinolaringología de SAP Filial Córdoba. Consenso Nacional de Rinitis Alérgica en Pediatría. Arch Argent Pediatr. 2009;107(1):67-81. Disponible en: https://www.sap.org.ar/uploads/consensos/consenso-nacional-de-rinitis-al-eacutergica-en-pediatr-iacutea.pdf
Garde JM, García-Avilés B, Marco N, Montahud C, Perona J. Rinoconjuntivitis alérgica. Protoc Diagn Pediatr. 2013;1:157-175. Disponible en: https://www.aeped.es/sites/default/files/documentos/rinitis.pdf
Keil T, Bockelbrink A, Reich A, Hoffmann U, Kamin W, Forster J, et al. The natural history of allergic rhinitis in childhood. Pediatr Allergy Immunol. 2010;21(6):962-969. DOI: 10.1111/j.1399-3038.2010.01046.x
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160. DOI: 10.1111/j.1398-9995.2007.01620.x
David P. Skoner, MD Pittsburgh, Pa. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(Suppl 1):S1-S8. DOI: 10.1067/mai.2001.115569
Frenkiel S, Becker A, Boisvert P, Small P, Bouchard J, Carr S, et al. Rhinitis: a practical and comprehensive approach to assessment and therapy. J Otolaryngol. 2007;36(Suppl 1):S5-S27. DOI: 10.2310/7070.2006.X002
Ownby DR, Adinoff AD. The appropriate use of skin testing and allergen immunotherapy in young children. J Allergy Clin Immunol. 1994;94(4):662-665. DOI: 10.1016/0091-6749(94)90171-6
Tefferi A. Blood eosinophilia: a new paradigm in disease, classification, diagnosis and treatment. Mayo Clin Proc. 2005;80(1):75-83. DOI: 10.1016/S0025-6196(11)62962-5
Jirapongsananuruk O, Vichyanond P. Nasal cytology in the diagnosis of allergic rhinitis in children. Ann Allergy Asthma Immunol. 1998;80:165-170. DOI: 10.1016/S1081-1206(10)62950-X
Gelardi M, Iannuzzi L, Quaranta N, Landi M, Passalacqua G. NASAL cytology: practical aspects and clinical relevance. Clin Exp Allergy. 2016;46(6):785-792. DOI: 10.1111/cea.12730
Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010;125(Suppl 2):S103-115. DOI: 10.1016/j.jaci.2009.12.989
Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015;152(2):197-206. DOI: 10.1177/0194599814562166
Custovic A, Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy. 2005;60(9):1112-1115. DOI: 10.1111/j.1398-9995.2005.00934.x
Bush RK, Portnoy JM, Saxon A,Terr AI, Wood RA. The medical effects of mold exposure. J Allergy Clin Immunol. 2006;117(2):326-333. DOI: 10.1016/j.jaci.2005.12.001
Tariq SM, Matthews SM, Stevens M, Hakim EA. Sensitization to alternaria and cladosporium by the age of 4 years. Clin Exp Allergy. 1996;26(7):794-798. DOI: 10.1111/j.1365-2222.1996.tb00610.x
Simons FER. H1-antihistamines in children. En: Simons FER (editor). Histamine and H1-antihistamines in allergic disease. EE. UU.: Marcel Dekker; 2002.
Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111(5):S835-S828. DOI: 10.1067/mai.2003.1550
Bousquet J, Bindslev-Jensen C, Canonica GW, Fokkens W, Kim H, Kowalski M, et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy. 2004;59(Suppl 77):S4-S16. DOI: 10.1111/j.1398-9995.2004.00577.x
Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, et al. Systematic review on the efficacy of fexonfenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Arch Allergy Immunol. 2011;156(1):1-15.
Bousquet J, van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl 5):S147-S334. DOI: 10.1067/mai.2001.118891
Dykewicz MS, Fineman S, Skoner D, Nicklas R, Lee R, Blessing-Moore J, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81(5 Pt 2):478-518. DOI: 10.1016/s1081-1206(10)63155-9
Ozdemir PG, Karadag AS, Selvi Y, Boysan M, Bilgili SG, Aydin A, et al. Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety. Int J Psychiatry Clin Pract. 2014;18(3):161-168. DOI: 10.3109/13651501.2014.907919
Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, et al. Food allergy: a practice parameter update-2014. J Allergy Clin Immunol. 2014;134(5):1016-1025. DOI: 10.1016/j.jaci.2014.05.013
Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005;5(13-14):1800-18008. DOI: 10.1016/j.intimp.2005.05.008
Nayak AS, Berger WE, LaForce CF, Urdaneta ER, Patel MK, Franklin KB, et al. Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. Allergy Asthma Proc. 2017;38(3):222-230. DOI: 10.2500/aap.2017.38.4050
Warner JO, ETAC Study Group. Early treatment of the atopic child. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months’ treatment and 18 months’ posttreatment follow-up. J Allergy Clin Immunol. 2001;108(6):929-937. DOI: 10.1067/mai.2001.120015
De Bruyne P, Christiaens T, Boussery K, Mehuys E, van Winckel M. Are antihistamines effective in children? A review of the evidence. Arch Dis Child. 2017;102(1):56-60. DOI: 10.1136/archdischild-2015-310416
Lee CF, Sun HL, Lu KH, Ku MS, Lue KH. The comparison of cetirizine, levocetirizine and placebo for the treatment of childhood perennial allergic rhinitis. Pediatr Allergy Immunol. 2009;20(5):493-499. DOI: 10.1111/j.1399-3038.2008.00816.x
Rapiejko P, Jurkiewicz D, Pietruszewska W, Zielnik-Jurkiewicz B, Woroń J, Lipiec A. Treatment strategy of allergic rhinitis in the face of modern world threats. Otolaryngol Pol. 2018;72(2):1-12. DOI: 10.5604/01.3001.0011.8057
Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings. J Pharm Sci. 2017;106(9):2312-2325. DOI: 10.1016/j.xphs.2017.04.004
Simons FE, Semus MJ, Goritz SS, Simons KJ. H1-antihistaminic activity of cetirizine and fexofenadine in allergic children. Pediatr Allergy Immunol. 2003;14(3):207-211. DOI: 10.1034/j.1399-3038.2003.00018.x
Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption / elimination / transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 2008; 60:717-33.
Salmun LM, Herron JM, Banfield C, Padhi D, Lorber R, Affrime MB. The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Clin Ther. 2000;22(5):613-621. DOI: 10.1016/S0149-2918(00)80048-X
Bronsky E, Boggs P, Findlay S, Gawchik S, Georgitis J, Mansmann H, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol. 1995;96(2):139-147. DOI: 10.1016/s0091-6749(95)70001-3
Berkowitz RB, McCafferty F, Lutz C, Bazelmans D, Godfrey P, Meeves S, et al. Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies. Clin Ther. 2006;28(10):1658-1669. DOI: 10.1016/j.clinthera.2006.10.023
Klimek L, Sperl A. Evidence-based treatment options for allergic diseases in otolaryngology: an update. HNO. 2013;61(6):525-538. DOI: 10.1007/s00106-013-2709-0
Cingi C, Muluk NB, Kagan I, Şahin E. Antileukotrienes in upper airway inflammatory diseases. Current Allergy Asthma Rep. 2015;15(11):64. DOI: 10.1007/s11882-015-0564-7
Baños-Zamora M, Somonte-Zamora DE, Morales-Pérez V. Leucotrienos y antileucotrienos en medicina basada en la evidencia. Rev Latinoam Patol Clin Med Lab. 2015;62(3):157-162. Disponible en: https://www.medigraphic.com/pdfs/patol/pt-2015/pt153d.pdf
Balanzat AM, Urrutigoity J, Abram L, Acuña T, Adot F, Aguerre V, et al. Consenso de Asma Bronquial. 2007. 2ª parte. Arch Argent Pediatr. 2008;106(2):162-175. Disponible en: https://www.sap.org.ar/docs/publicaciones/archivosarg/2008/v106n2a13.pdf
Li AM, Abdullah VJ, Tsen CS, Au CT, Lam HS, So HK, et al. Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis—a randomized placebo-controlled study. Pediatr Pulmonol. 2009;44(11):1085-1092. DOI: 10.1002/ppul.21102
Klimek L, Sperl A, Becker S, Mösges R, Tomazic PV. Current therapeutical strategies for allergic rhinitis. Expert Opin Pharmacother. 2019;20(1):83-89. DOI: 10.1080/14656566.2018.1543401
Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-374. DOI: 10.1016/j.jaci.2016.03.025
Pascual-Pérez JM, Callén-Blecua M, Bercedo-Sanz A, Praena-Crespo M, Montón-Álvarez JL, Bamonde-Rodríguez L, et al. El pediatra de atención primaria y la rinitis alérgica. España: Asociación Española de Pediatría de Atención Primaria; 2016.
De Corso E, Anzivino R, Galli J, Baroni S, Di Nardo W, De Vita C, et al. Antileukotrienes improve naso-ocular symptoms and biomarkers in patients with NARES and asthma. Laryngoscope. 2019;129(3):551-557. DOI: 10.1002/lary.27576
Arruti-Pérez E. Fibrosis quística. Análisis de la casuística pediátrica del Hospital Universitario Donostia. País Vasco: Universidad del País Vasco/Faacultad de Medicina y Odontología; 2017. Disponible en: https://addi.ehu.es/bitstream/handle/10810/31027/TFG_Arruti_Perez_Rev.pdf?sequence
Heffler E, Brussino L, del Giacco S, Paoletti G, Minciullo PL, Varricchi G, et al. New drugs in early-stage clinical trials for allergic rhinitis. Exp Opin Invest Drugs. 2019;28(3):267-273. DOI: 10.1080/13543784.2019.1571581
Cobanoglu B, Toskala E, Ural A, Cingi C. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2013;13(2):203-208. DOI: 10.1007/s11882-013-0341-4
Reiss T, Allman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J AIlergy Clin Immunol. 1996;98(3):528-534. DOI: 10.1016/s0091-6749(96)70086-6
Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope. 2010;120(9):1718-1723. DOI: 10.1002/lary.20941
Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32(7):1020-1028. DOI: 10.1046/j.1365-2222.2002.01422.x
Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88(6):592-600. DOI: 10.1016/S1081-1206(10)61891-1
Wilson AM, Orr LC, Coutie WJ, Sims EJ, Lipworth BJ. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy. 2002;32(1):126-132. DOI: 10.1046/j.0022-0477.2001.01252.x
Wilson AM, White PS, Gardiner Q, Nassif R, Lipworth BJ. Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in a real life rhinology clinic setting. Rhinology. 2001;39(3):142-146.
Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: a randomized, double-blind clinical trial. Indian J Pharmacol. 2016;48(6):649-653. DOI: 10.4103/0253-7613.194854
Ciebiada M, Gorska-Ciebiada M, Barylski M, Kmiecik T, Gorski P. Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. Am J Rhinol Allergy. 2011;25(1):e1-6. DOI: 10.2500/ajra.2011.25.3540
Seth D, Kamat D. Intranasal steroid therapy for allergic rhinitis. Pediatr Ann. 2019;48(1):e43-e48. DOI: 10.3928/19382359-20181212-01
Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 11998;317(7173):1624-1629. DOI: 10.1136/bmj.317.7173.1624
Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96(6):779-786. DOI: 10.1016/S1081-1206(10)61339-7
Stern MA, Wade AG, Ridout SM, Cambell L. Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine. Ann Allergy Asthma Immunol. 1998;81:354-358. DOI: 10.1016/s1081-1206(10)63128-6
Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001;108(Suppl 1):S45-S53. DOI: 10.1067/mai.2001.115566
Berger W, Bousquet J, Fox AT, Just J, Muraro A, Nieto A, Valovirta E, Wickman M, Wahn U. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy 2016;71:1219-22.
Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc 2018;39:110-16.
Graft D, Aaronson D, Chervinsky P, Kaiser H, Melamed J, Pedinoff A, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol. 1996;98(4):724-731. DOI: 10.1016/s0091-6749(96)70119-7
Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Allergy 1997;52(suppl 36):S29- S32.
Fokkens WJ, Godthelp T, Holm AF, Blom H, Klein-Jan A. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy. 1997;52(Suppl 36):29-32. DOI: 10.1111/j.1398-9995.1997.tb04819.x
Naclerio RM, Adkinson NF Jr, Creticos PS. Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies. J Allergy Clin Immunol. 1993;92(5):717-721. DOI: 10.1016/0091-6749(93)90015-8
Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol. 1999;104(4 Pt 1):S144-S149. DOI: 10.1016/s0091-6749(99)70310-6
Minshall E, Ghaffar O, Cameron L, O’Brien F, Quinn H, Rowe-Jones J, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg. 1998;118(5):648-654. DOI: 10.1177/019459989811800514
Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. Am J Otolaryngol. 2008;29(6):403-413. DOI: 10.1016/j.amjoto.2007.11.004
Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary- adrenal-axis activity. J Allergy Clin Immunol. 1998;101(4 Pt 1):470-474. DOI: 10.1016/S0091-6749(98)70354-9
Wilson AM, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol. 1998;102(4 Pt 1):598-604. DOI: 10.1016/s0091-6749(98)70275-1
Fuhlbrigge AL, Kelly HW. Inhaled corticosteroids in children: effects on bone mineral density and growth. Lancet Respir Med. 2014;2(6):487-496. DOI: 10.1016/S2213-2600(14)70024-4
Rachelefsky GS, Chervinsky P, Meltzer EO, et al. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray (Vancenase AQ [VNS]) on long term growth in children. J Allergy Clin Immunol. 1998;101(Suppl):S236.
Weinstein S, Qaqundah P, Georges G, Nayak A. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Ann Allergy Asthma Immunol. 2009;102(4):339-347. DOI: 10.1016/S1081-1206(10)60340-7
Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407-413.
D’Urzo, Karpel JP, Busse WW, Boulet LP, Monahan ME, Lutsky B, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin. 2005;21(8):1281-1289. DOI: 10.1185/030079905X56402
Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol. 2000;106(Suppl 4):S179-S190. DOI: 10.1067/mai.2000.110038
Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1-12. Disponible en: http://www.jiaci.org/issues/vol22issue1/1.pdf
Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth-van Wijk R, et al. EAACI Guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;43(4):765-798. DOI: 10.1111/all.13317
Halken S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar O, et al. EAACI guidelines on allergen immunotherapy: prevention of allergy. Pediatr Allergy Immunol. 2017;28(8):728-745. DOI: 10.1111/pai.12807
Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72(11):1597-1631. DOI: 10.1111/all.13201
Arasi S, Corsello G, Villani A, Battista-Pajno G. The future outlook on allergen immunotherapy in children: 2018 and beyond. Ital J Pediatr. 2018;44(1):80. DOI: 10.1186/s13052-018-0519-4
Noon L. Prophylactic inoculation against hay fever. Lancet. 1911(4580):1572-1573. DOI: 10.1016/S0140-6736(00)78276-6
Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017;140(6):1485-1498. DOI: 10.1016/j.jaci.2017.10.010
Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621-631. DOI: 10.1016/j.jaci.2013.12.1088
Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012;2(1):2. DOI: 10.1186/2045-7022-2-2
Novak N, Mete N, Bussmann C, Maintz L, Bieber T, Akdis M, et al. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J Allergy Clin Immunol. 2012;130(5):1153-1158. DOI: 10.1016/j.jaci.2012.04.039
van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Söllner S, Akdis DG, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013;131(4):1204-1212. DOI: 10.1016/j.jaci.2013.01.014
Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med. 2008;205(12):2887-298. DOI: 10.1084/jem.20080193
Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. JAMA. 2017;317(6):615-625. DOI: 10.1001/jama.2016.21040
James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 2011;127(2):509-516. DOI: 10.1016/j.jaci.2010.12.1080
Renand A, Archila LD, McGinty J, Wambre E, Robinson D, Hales BJ, et al. Chronic cat allergen exposure induces a TH2 cell-dependent IgG4 response related to low sensitization. J Allergy Clin Immunol. 2015;136(6):1627-1635. DOI: 10.1016/j.jaci.2015.07.031
Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol. 2017;178(7):4658-4666. DOI: 10.4049/jimmunol.178.7.4658
Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol. 2005;116(1):73-79. DOI: 10.1016/j.jaci.2005.03.011
Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet. 1998;351(9103):629-632. DOI: 10.1016/S0140-6736(97)07055-4
Wilson DR, Nouri-Aria KT, Walker SM, Pajno GB, O’Brien F, Jacobson MR, et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol. 2001;107(6):971-976. DOI: 10.1067/mai.2001.115483
Lao-Araya M, Steveling E, Scadding GW, Durham SR, Shamji MH. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J Allergy Clin Immunol. 2014;134(5):1193-1195. DOI: 10.1016/j.jaci.2014.07.029
Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28(1):18-29. DOI: 10.1111/pai.12661
Tran MM, Lefebvre DL, Dharma C, Dai D, Lou WYW, Subbarao P, et al. Predicting the atopic march: results from the Canadian Healthy Infant Longitudinal Development Study. J Allergy Clin Immunol. 2018;141(2):601-607. DOI: 10.1016/j.jaci.2017.08.024
Khan SJ, Dharmage SC, Matheson MC, Gurrin LC. Is the atopic march related to confounding by genetics and early-life environment? A systematic review of sibship and twin data. Allergy. 2018;73(1):17-28. DOI: 10.1111/all.13228
Hatzler L, Panetta V, Lau S, Wagner P, Bergmann RL, Illi S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol. 2012;130(4):894-901. DOI: 10.1016/j.jaci.2012.05.053
Matricardi PM. Allergen-specific immunoprophylaxis: toward secondary prevention of allergic rhinitis? Pediatr Allergy Immunol. 2014;25(1):15-18. DOI: 10.1111/pai.12200
Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251-256. DOI: 10.1067/mai.2002.121317
Möller C, Dreborg S, Lanner A, Björkstén B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy. 1986;41(4):271-279. DOI: 10.1111/j.1398-9995.1986.tb02028.x
Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco AD, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101(2):206-211. DOI: 10.1016/s1081-1206(10)60211-6
Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, de Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851-857. DOI: 10.1016/j.jaci.2004.07.012
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943-948. DOI: 10.1111/j.1398-9995.2007.01451.x
Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529-538. DOI: 10.1016/j.jaci.2017.06.014
Pajno GB, Bernardini R, Peroni D, Arasi S, Martelli A, Landi M, et al. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatr. 2017;43(1):13. DOI: 10.1186/s13052-016-0315-y
Bianchi A, Tsilochristou O, Gabrielli F, Tripodi S, Matricardi PM. The Smartphone: a novel diagnostic tool in pollen allergy? J Investig Allergol Clin Immunol. 2016;26(3):204-207. DOI: 10.18176/jiaci.0060
Stringari G, Tripodi S, Caffarelli C, Dondi A, Asero R, di Rienzo-Businco A, et al. Italian pediatric allergy network (I-PAN). The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol. 2014;134(1):75-81. DOI: 10.1016/j.jaci.2014.01.042
Weyer A, Donat N, L’Heritier C, Juilliard F, Pauli G, Soufflet B, et al. Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract. Allergy. 1981;36(5):309-317. DOI: 10.1111/j.1398-9995.1981.tb01582.x
Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy. 2000;55(12):1142-1147. DOI: 10.1034/j.1398-9995.2000.00655.x
Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G, et al. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy. 2003;33(12):1641-1647. DOI: 10.1111/j.1365-2222.2003.01809.x
Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(1):160-166. DOI: 10.1016/j.jaci.2008.10.009
Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol. 2006;117(2):263-268. DOI: 10.1016/j.jaci.2005.09.054
Stelmach I, Kaluzińska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P, et al. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy. 2012;67(3):312-320. DOI: 10.1111/j.1398-9995.2011.02758.x
Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, et al. Efficacy of house dust mite sublingual immunotherapy tablet in north American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016;138(6):1631-1638. DOI: 10.1016/j.jaci.2016.06.044
Okubo K, Masuyama K, Imai T, Okamiya K, Stage BS, Seitzberg D, et al. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. J Allergy Clin Immunol. 2017;139(6):1840-1848. DOI: 10.1016/j.jaci.2016.09.043
Ott H, Sieber J, Brehler R, Fölster-Holst R, Kapp A, Klimek L, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64(9):1394-1401. DOI: 10.1111/j.1398-9995.2009.02194.x
Bergmann KC, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(6):1608-1614.
Rice JL, Diette GB, Suárez-Cuervo C, Brigham EP, Lin SY, Ramanathan M Jr, et al. Allergen-specific immunotherapy in the treatment of pediatric asthma: a systematic review. Pediatrics. 2018;141(5):e20173833. DOI: 10.1542/peds.2017-3833
Bousquet J, Bedbrook A, Czarlewski W, Onorato GL, Arnavielhe S, Laune D, et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy. 2019;9:16. DOI: 10.1186/s13601-019-0252-0
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Revista Alergia México